Block­buster fran­chise ex­pands: Re­gen­eron shares spike on new high-dose Eylea da­ta

Re­gen­eron un­veiled a pair of tri­al wins Thurs­day, se­cur­ing a way to un­lock a like­ly ex­ten­sion to its multi­bil­lion-dol­lar Eylea fran­chise and a stock price bump too.

The com­pa­ny un­veiled two non­in­fe­ri­or­i­ty hits on pri­ma­ry end­points in vi­sion gains for a pair of piv­otal tri­als in­ves­ti­gat­ing its high-dose ver­sion of the megablock­buster Eylea with longer, 12- and 16-week dos­ing reg­i­mens (com­pared to a 2 mg ver­sion with an 8-week dos­ing reg­i­men) in pa­tients with di­a­bet­ic mac­u­lar ede­ma (DME) and wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (wAMD).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER